Sort
53,477 grants matching “addiction”
Associative learning, decision-making, and addiction
$3,285,849Geoffrey Schoenbaum · National Institute On Drug Abuse · ZIA · FY2016 · DA
A novel therapeutic to ameliorate chronic pain and reduce opiate use
$3,283,785Boris Tabakoff · Lohocla Research Corporation · UH3 · FY2022 · DA
State-dependent Decision-making in Brainwide Neural Circuits
$3,280,464Liam M Paninski · Columbia Univ New York Morningside · U19 · FY2024 · NS
Neurobiology Of Relapse To Opiate and Psychostimulant Drugs
$3,278,935Yavin Shaham · National Institute On Drug Abuse · ZIA · FY2025 · DA
HIV Prevention Trials Network: Network Laboratory
$3,273,493Susan H Eshleman · Johns Hopkins University · U01 · FY2008 · AI
A novel therapeutic to ameliorate chronic pain and reduce opiate use
$3,270,473Boris Tabakoff · Lohocla Research Corporation · UG3 · FY2020 · DA
Characterization of neuronal ensembles activated during cue-induced reward seeking
$3,269,973Bruce Hope · National Institute On Drug Abuse · ZIA · FY2024 · DA
State-dependent Decision-making in Brainwide Neural Circuits
$3,266,100Liam M Paninski · Columbia Univ New York Morningside · U19 · FY2025 · NS
Arylepoxamides: A new class of potent, safer analgesics
$3,263,463Ying-Xian Pan · Sloan-Kettering Inst Can Research · UG3 · FY2019 · DA
Associative learning, decision-making, and addiction
$3,263,413Geoffrey Schoenbaum · National Institute On Drug Abuse · ZIA · FY2017 · DA
Neurogenomics of Vulnerability and Resilience to Mental Health Syndromes in Response to Extreme Life Events
$3,263,217Michael L Platt · University Of Pennsylvania · RF1 · FY2025 · MH
Neuronal networks for control of eye movement
$3,254,376Okihide Hikosaka · National Eye Institute · ZIA · FY2024 · EY
TMP-301, A Negative Allosteric Modulator of type 5 metabotropic glutamate receptors (mGluR5), for Treatment of Cocaine Use Disorder
$3,250,400Charles Daniel Meyers · Tempero Bio, Inc. · U01 · FY2023 · DA
Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders
$3,249,130Gretchen L Snyder · Intra-Cellular Therapies, Inc. · UG3 · FY2019 · DA
Integrating Addiction Research in Health Systems: The Addiction Research Network
$3,246,804Cynthia I Campbell · Kaiser Foundation Research Institute · UG1 · FY2019 · DA
Evaluation of psilocybin as an adjunctive treatment for opioid use disorder in methadone-maintained patients who continue to use illicit opioids
$3,244,725Michael Parks Bogenschutz · New York University School Of Medicine · UG3 · FY2024 · DA
Mouse models of stress disorders and addiction
$3,243,936Andrew Holmes · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2025 · AA
Southern Consortium Node of the Clinical Trials Network
$3,243,031Kathleen Theresa Brady · Medical University Of South Carolina · UG1 · FY2019 · DA
Associative learning, decision-making, and addiction
$3,242,017Geoffrey Schoenbaum · National Institute On Drug Abuse · ZIA · FY2018 · DA
Project-003
$3,235,924Madhukar H Trivedi · Ut Southwestern Medical Center · UG1 · FY2025 · DA
NIDA Clinical Trials Network: Big South/West Node (CTN-0159)
$3,235,924Madhukar H Trivedi · Ut Southwestern Medical Center · UG1 · FY2025 · DA
RCMI@Morgan: Center for Urban Health Disparities Research and Innovation
$3,233,840Hongtao Yu · Morgan State University · U54 · FY2019 · MD
Effects of full-spectrum cannabidiol on alcohol consumption and alcohol use disorder phenotypes: implications for precision medicine
$3,227,517Hollis C Karoly · University Of Colorado Denver · R01 · FY2025 · AA
LIGHT and Lymphotoxin targeting for the treatment of chronic orofacial pain conditions
$3,227,250Armen N Akopian · University Of Texas Hlth Science Center · R01 · FY2019 · DE
Conte Center: Understanding Latent Cause Inference in Health and Illness
$3,225,980Yael Niv · Princeton University · P50 · FY2024 · MH